A comparative study of the effects of Tocilizumab?, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm

Phase 2

• Conditions: Covid-19.; U07.1; Covid-19 disease

• Registration Number: IRCT20200525047570N1
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 August 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Lack of a specific clinical disease
Non-use of a particular drug
No pregnancy

Exclusion Criteria

A specific clinical disease
Taking a particular drug
Pregnancy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood ferritin levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Blood C-reactive protein levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Blood creatine Phosphokinase levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Low-density lipoprotein levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Lung tissue. Timepoint: Days 1 and 14. Method of measurement: Computed tomography CT-scan.;Blood Lymphocyte levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Blood Neutrophil levels. Timepoint: Days 1-3-7-10-14. Method of measurement: ELISA kit.;Partial pressure of carbon dioxide (PCO2). Timepoint: Days 1-3-7-10-14. Method of measurement: Arterial blood gas test.

Secondary Outcome Measures

Name	Time	Method
Tumor necrosis factor alpha, TNFa. Timepoint: Days 1, 3 ,7 , 14. Method of measurement: ELISA Kit.;Interleukin 1. Timepoint: Days 1 ,3 ,7 , 14. Method of measurement: ELISA Kit.;Interleukin 6. Timepoint: Days 1, 3, 7, 14. Method of measurement: ELISA Kit.;Interleukin 18. Timepoint: Days 1, 3, 7, 14. Method of measurement: ELISA Kit.